...
首页> 外文期刊>Therapeutic advances in drug safety. >Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access
【24h】

Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access

机译:纳洛酮对阿片类药物过量的安全性审查:新技术和扩大公众获取的实际考虑

获取原文
           

摘要

Opioid overdose and mortality have increased at an alarming rate prompting new public health initiatives to reduce drug poisoning. One initiative is to expand access to the opioid antidote naloxone. Naloxone has a long history of safe and effective use by organized healthcare systems and providers in the treatment of opioid overdose by paramedics/emergency medicine technicians, emergency medicine physicians and anesthesiologists. The safety of naloxone in a prehospital setting administered by nonhealthcare professionals has not been formally established but will likely parallel medically supervised experiences. Naloxone dose and route of administration can produce variable intensity of potential adverse reactions and opioid withdrawal symptoms: intravenous administration and higher doses produce more adverse events and more severe withdrawal symptoms in those individuals who are opioid dependent. More serious adverse reactions after naloxone administration occur rarely and may be confounded by the effects of other co-intoxicants and the effects of prolonged hypoxia. One component of the new opioid harm reduction initiative is to expand naloxone access to high-risk individuals (addicts, abusers, or patients taking high-dose or extended-release opioids for pain) and their close family or household contacts. Patients or their close contacts receive a naloxone prescription to have the medication on their person or in the home for use during an emergency. Contacts are trained on overdose recognition, rescue breathing and administration of naloxone by intramuscular injection or nasal spraying of the injection prior to the arrival of emergency medical personnel. The safety profile of naloxone in traditional medical use must be considered in this new context of outpatient prescribing, dispensing and treatment of overdose prior to paramedic arrival. New naloxone delivery products are being developed for this prehospital application of naloxone in treatment of opioid overdose and prevention of opioid-induced mortality.
机译:阿片类药物的过量使用和死亡率以惊人的速度增长,促使人们采取了新的公共卫生措施来减少药物中毒。一种举措是扩大使用阿片类解毒剂纳洛酮的机会。纳洛酮由有组织的医疗保健系统和提供者在医护人员/急诊医学技术人员,急诊医学医生和麻醉师对类阿片药物过量进行治疗方面具有安全有效的悠久历史。尚未正式确定纳洛酮在非医疗保健专业人员管理的院前环境中的安全性,但可能会与医学监督经验并驾齐驱。纳洛酮的剂量和给药途径可产生不同程度的潜在不良反应和阿片类药物戒断症状:静脉内给药和更高剂量在阿片类药物依赖的个体中产生更多的不良事件和更严重的戒断症状。纳洛酮给药后,更严重的不良反应很少发生,并且可能与其他共毒物的影响和长期缺氧的影响相混淆。新的减少阿片类药物危害举措的一个组成部分是将纳洛酮的使用范围扩大到高风险人群(成瘾者,滥用者或因服用大剂量或长期释放阿片类药物而引起疼痛的患者)及其亲密家庭或家庭接触者。患者或他们的近亲会收到纳洛酮处方,以便在紧急情况下将药物放在自​​己的人或家里。在急诊医护人员到达之前,通过肌肉注射或鼻腔喷洒对接触者进行过量识别,急救呼吸和纳洛酮的管理方面的培训。在护理人员到达之前门诊开处方,配药和用药过量的新情况下,必须考虑纳洛酮在传统医学用途中的安全性。正在为这种院前应用纳洛酮治疗阿片类药物过量和预防阿片类药物引起的死亡而开发新的纳洛酮递送产品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号